Business
CORRECTING and REPLACING Twist Bioscience Announces Completion of $50 Million Offering Priced At-The-Market
SAN FRANCISCO--(BUSINESS WIRE)-- Please replace the release dated January 27, 2020 with the following corrected version due to revisions to the headline. The
About this update from Twist Bioscience Corporation
[{"type":"text","content":" SAN FRANCISCO--(BUSINESS WIRE)--\nPlease replace the release dated January 27, 2020 with the following corrected version due to revisions to the headline.\n\n\nThe corrected release reads:\n\n\nTWIST BIOSCIENCE ANNOUNCES COMPLETION OF $50 MILLION OFFERING PRICED AT-THE-MARKET\n\n\nTwist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has issued approximately 2.24 million shares of its common stock at an average price of approximately $22.32 per share, raising approximately $49.98 million in gross proceeds.\n\n\nOn December 18, 2019, Twist filed a prospectus supplement with the Securities and Exchange Commission for the sale of up to $50.0 million in shares of its common stock through an at-the-market offering with Cowen and Company, LLC as its agent. The prospectus supplement relates to Twist’s registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on December 13, 2019. Twist intends to use the proceeds from the at-the-market offering for working capital purposes and to fund its growth.\n\n\nAbout Twist Bioscience Corporation\n\n\nTwist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.\n\n\nFollow us on Twitter | Facebook | LinkedIn | YouTube\n\n\nLegal Notice Regarding Forward-Looking Statements\n\n\nThis press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations...